Blood Flow Restriction Following Hip Arthroscopy
NCT04113759
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Labral Tear, Glenoid
- Femoral Acetabular Impingement
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Rush University Medical Center
- Last updated on ClinicalTrials.gov
- December 5, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- Rush University Medical Center · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.